Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 4/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 3/20 | 0.31 |
| ▸ | CCNH | P51946 | 3/20 | 0.31 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL25211512 | 0.82 | CCNT1 (0.44) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25028896 | 0.77 | GSK3B (0.45) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25029296 | 0.73 | GSK3B (0.41) | GSK3BDYRK1ANFATC1CDK7CCNH | |
| SCHEMBL29363610 | 0.73 | GSK3B (0.41) | GSK3BDYRK1ANFATC1CDK7CCNH | |
| SCHEMBL29364064 | 0.72 | GPR119 (0.50) | ALOX5APFEN1 | |
| SCHEMBL25278423 | 0.72 | GPR119 (0.50) | ALOX5APFEN1 | |
| SCHEMBL25028901 | 0.70 | DYRK1A (0.45) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL29363858 | 0.70 | DYRK1A (0.45) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25028895 | 0.70 | DYRK1A (0.45) | CCNKCDK12CCNT1CCNE1CDK2 | |
| Trifluoroacetic Acid SCHEMBL29361498 | 0.69 | CCNT1 (0.42) | CCNKCDK12CCNT1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCNK 2842/4885CDK12 1192/4885CCNT1 2902/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | CCNK 3289/4885CDK12 1193/4885CCNT1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.